... People with BRCA mutations had the longest PFS after taking Rubraca, meaning they saw the most benefit from this therapy. People who had other genetic mutations that led to problems with DNA repair also had a longer PFS. Even people who had tumors with normal DNA-repair abilities saw a benefit from Rubraca, although not quite to the same extent. ...
How Do Ovarian Cancer Maintenance Treatments Work?
... People with BRCA mutations had the longest PFS after taking Rubraca, meaning they saw the most benefit from this therapy. People who had other genetic mutations that led to problems with DNA repair also had a longer PFS. Even people who had tumors with normal DNA-repair abilities saw a benefit from Rubraca, although not quite to the same extent. ...
... for Ovarian Cancer — American Cancer Society Phases of Clinical Trials — American Cancer Society How We Treat Ovarian Cancer — Dana-Farber Cancer Institute Clovis Oncology, Inc,, AstraZeneca Pharmaceuticals LP, and GlaxoSmithKline LLC; Withdrawal of Approval of the Indications for Advanced Ovarian Cancer for Poly (ADP-Ribose) Polymerase Inhibitors Rubraca ...
7 Ovarian Cancer Treatment Options
... for Ovarian Cancer — American Cancer Society Phases of Clinical Trials — American Cancer Society How We Treat Ovarian Cancer — Dana-Farber Cancer Institute Clovis Oncology, Inc,, AstraZeneca Pharmaceuticals LP, and GlaxoSmithKline LLC; Withdrawal of Approval of the Indications for Advanced Ovarian Cancer for Poly (ADP-Ribose) Polymerase Inhibitors Rubraca ...
... other short-term or permanent side effects, including kidney damage, hearing loss, neuropathy, and bone marrow damage leading to different types of cancer.Targeted TherapyVarious targeted therapy drugs are used to treat ovarian cancer, including: Angiogenesis inhibitors such as Avastin (bevacizumab) PARP inhibitors, including Lynparza (olaparib) and Rubraca ...
Stage 4 Ovarian Cancer Explained
... other short-term or permanent side effects, including kidney damage, hearing loss, neuropathy, and bone marrow damage leading to different types of cancer.Targeted TherapyVarious targeted therapy drugs are used to treat ovarian cancer, including: Angiogenesis inhibitors such as Avastin (bevacizumab) PARP inhibitors, including Lynparza (olaparib) and Rubraca ...
... There are currently three FDA-approved PARP inhibitors available: Niraparib (Zejula) Rucaparib (Rubraca) Olaparib (Lynparza) Each can be given to women with or without BRCA gene mutations. ...
... PARP inhibitors are used as maintenance therapy after chemotherapy with a platinum-based drug and include: Niraparib (Zejula), which doesn’t require a biomarker Olaparib (Lynparza), used for cancers with BRCA1 or BRCA2 mutations Olaparib with bevacizumab, used for cancer cells with high genomic instability, with or without a BRCA mutation Rucaparib (Rubraca ...
Targeted Therapies for Ovarian Cancer: 8 New Treatments and Recent Advances
... PARP inhibitors are used as maintenance therapy after chemotherapy with a platinum-based drug and include: Niraparib (Zejula), which doesn’t require a biomarker Olaparib (Lynparza), used for cancers with BRCA1 or BRCA2 mutations Olaparib with bevacizumab, used for cancer cells with high genomic instability, with or without a BRCA mutation Rucaparib (Rubraca ...
... Drugs in this category that may be prescribed for ovarian cancer include Zejula (Niraparib), Lynparza (Olaparib), and Rubraca (Rucaparib).PARP inhibitors come in the form of pills or capsules. People who are prescribed these drugs typically take them once a day by mouth. ...
What To Expect From Ovarian Cancer Maintenance Treatment
... Drugs in this category that may be prescribed for ovarian cancer include Zejula (Niraparib), Lynparza (Olaparib), and Rubraca (Rucaparib).PARP inhibitors come in the form of pills or capsules. People who are prescribed these drugs typically take them once a day by mouth. ...
... PARP inhibitors can block PARP without affecting healthy cells.PARP inhibitors available to treat ovarian cancer as of April 2025 include: Niraparib (Zejula) Olaparib (Lynparza) Rucaparib (Rubraca) PARP inhibitors are typically prescribed to be taken orally (by mouth) every day.Antibody-Drug ConjugatesAntibody-drug conjugates (ADCs) are a newer type ...
Platinum Resistance in Ovarian Cancer Treatment: What You Need To Know
... PARP inhibitors can block PARP without affecting healthy cells.PARP inhibitors available to treat ovarian cancer as of April 2025 include: Niraparib (Zejula) Olaparib (Lynparza) Rucaparib (Rubraca) PARP inhibitors are typically prescribed to be taken orally (by mouth) every day.Antibody-Drug ConjugatesAntibody-drug conjugates (ADCs) are a newer type ...
... Examples of PARP inhibitors include Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib).Testing for BRCA MutationsDoctors can find BRCA mutations through genetic testing. This process involves collecting a blood or saliva sample, which is sent to a laboratory. ...
BRCA Gene Mutations: What To Know About Ovarian Cancer Risk
... Examples of PARP inhibitors include Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib).Testing for BRCA MutationsDoctors can find BRCA mutations through genetic testing. This process involves collecting a blood or saliva sample, which is sent to a laboratory. ...
... PARP inhibitors include olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). PARP inhibitors make it harder for cancer cells to repair DNA damage, leaving them more vulnerable. ...
Recurrent Ovarian Cancer Explained
... PARP inhibitors include olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). PARP inhibitors make it harder for cancer cells to repair DNA damage, leaving them more vulnerable. ...
... Drugs in the PARP inhibitor family include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula).Mirvetuximab soravtansine-gynx (Elahere) is a newer targeted therapy option. This drug is a type of antibody drug conjugate. ...
Join
Your Privacy Choices
